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Abstract: Sequencing of the human genome has permitted the development of genome-wide
association studies (GWAS) to analyze the genetics of a number of complex disorders such as
depression, anxiety and substance abuse. Thanks to their ability to analyze huge cohort sizes,
these studies have successfully identified thousands of loci associated with a broad spectrum of
complex diseases. Disconcertingly, the majority of these GWAS hits occur in non-coding regions of
the genome, much of which controls the cell-type-specific expression of genes essential to health.
In contrast to gene coding sequences, it is a challenge to understand the function of this non-coding
regulatory genome using conventional biochemical techniques in cell lines. The current commentary
scrutinizes the field of complex genetics from the standpoint of the large-scale whole-genome functional
analysis of the promoters and cis-regulatory elements using chromatin markers. We contrast these
large scale quantitative techniques against comparative genomics and in vivo analyses including
CRISPR/CAS9 genome editing to determine the functional characteristics of these elements and to
understand how polymorphic variation and epigenetic changes within these elements might contribute
to complex disease and drug response. Most importantly, we suggest that, although the role of
chromatin markers will continue to be important in identifying and characterizing enhancers,
more emphasis must be placed on their analysis in relevant in-vivo models that take account of
the appropriate cell-type-specific roles of these elements. It is hoped that offering these insights might
refocus progress in analyzing the data tsunami of non-coding GWAS and whole-genome sequencing
“hits” that threatens to overwhelm progress in the field.
Keywords: complex disease; gene regulation; chromatin modification; comparative genomics;
CRISPR genome editing; promoter; enhancer; polymorphisms; mental health; alcohol abuse;
anxiety; pharmacogenomics
1. Introduction
Genome-wide association studies (GWAS) have revolutionized the genetic analysis of human
disease. Ever since the sequencing of the human genome and the development of gene chip technologies,
GWAS has been able to scan hundreds of thousands of genetic variants in tens or even hundreds
of thousands of patients to deliver a greater understanding of the genetic architecture of complex
human disease. Thanks to GWAS, the number of genetic loci with significant association with complex
disease (p < 1 × 10−6), known as GWAS “hits”, now number in the thousands [1]. One promising
use of the data generated by these GWAS studies is in the calculation of polygenic risk scores that,
by adding together the disease risk of many individual alleles, seek to predict the likelihood of
developing a complex disease [2]. From the standpoint of functionality, when a GWAS “hit” occurs
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within a gene coding sequence we can use a plethora of well-understood biochemical methodologies
to understand the molecular mechanisms affected by a specific allelic variant. Frustratingly, however,
the vast majority of these GWAS hits do not occur neatly in coding regions but within the 98% of
the genome that does not encode protein; a region of the genome referred to as the non-coding
genome [3]. Another more recent and widely focused study further confirmed that the majority of
GWAS hits were non-coding but also made the somewhat bewildering prediction that complex human
diseases are probably influenced by the combined input of many hundreds if not thousands of genetic
variants [4]. This study further recommended that a much better understanding of cell-type-specific
regulatory networks and the regulatory genome must be achieved before an understanding of
the genetic basis of complex disease can be gained [4].
What Is the Regulatory Genome?
Most scientists with a passing knowledge of molecular genetics are aware of the existence of
sequences adjacent to the transcriptional start sites of genes called promotors [5]. These act to attract
and orientate the pre-initiation complex (PIC) to the transcriptional start site (TSS) of genes [6]. The PIC
comprises a complex of proteins that include RNA polymerase II (RNApolII) [7], which is now known
to initiate transcription from promoters bidirectionally [8]. Attempts have been made to classify
promoters based on their tissue specificity, interaction with histones, the relative integrity of their
TSSs and the histone methylation signatures (triple methylation of lysine 4 of histone 3; H3K4me3)
associated with their activity [9]. More recent Drosophila-based studies stratified promoters according
to the absence or presence of TATA box or DPE sequences [10]. Promoter regions are often associated
with regions of DNA called CpG islands that contain a much higher proportion of CpG dinucleotides
than the surrounding genome. These CpGs act as a target of the DNA methyltransferase (DNMT)
enzyme, which methylate’s the cytosine within the CpG dinucleotide to form 5-methyl cytosine
(5mC) [11]. Changes in the methylation of CpG islands have been associated with disease states such
as alcohol and drug addiction [12], and altered CpG methylation has a significant effect of levels of
promoter activity [13]. Critically, many promoters rely on the proximity of other elements, such as
enhancers, to drive their activity in specific cells and tissues [14]. It was estimated by the ENCODE
consortium that these enigmatic and poorly understood enhancer sequences make up as much as 10%
of the human genome, five times greater than the coding genome, and may comprise over 2 million
enhancers [15]. However, in light of the increasing evidence for a role of non-coding regulatory elements
in susceptibility to complex disease, there are concerns that our limited ability to detect and functional
characterize cell-type-specific enhancers threatens to derail efforts to understand the molecular basis of
complex disease and to produce potential personalized therapies. So what are enhancers?
2. Identifying Enhancer Sequences; Lessons from Developmental Biology
Classically, an enhancer is defined as a region of non-coding DNA that is required to increase
the activity of a promoter region. In contrast to promoter regions, enhancers are also defined as
being orientation- and distance- independent [16]. From an evolutionary perspective, it is instructive
that even the most complex single-cell organisms lack enhancer sequences [17]. Indeed, there is an
emerging consensus that enhancers evolved to allow cells to communicate with each other to build
complex multicellular systems and to organize cell division and differentiation during the embryonic
development of the first multicellular organisms [17].
Although most complex diseases affect adult humans, many of the lesions leading to disease
may be developmental in origin, and it is through developmental biology that we have received our
most revealing insights into enhancer biology. For example, pivotal studies on the causes of human
developmental disorders such as preaxial–polydactyly (PPD) [18] and Pierre Robin sequence (PRS) [19]
have emphasized the huge genomic distances (1.5 and 1Mb respectively) over which many enhancers
affect the activity of the promoters they regulate. Both of these studies also emphasize the extreme
context-dependency of many enhancer sequences. Thus, the activity of the PRS enhancer sequences
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studied by the Wysocka lab was only revealed in cranial neural crest cells and could not be detected in
stem cells [19]. These studies highlight that enhancers are required to allow genomes of multicellular
organisms to communicate during their embryonic development and, most importantly, to respond
appropriately within the correct context and to the appropriate cues [20]. In this regard, enhancers
are like the “sense organs” of the genome in that they detect whether a specific cell–cell interaction or
environmental response has triggered a particular set of signal transduction cascades [21]. These signal
transduction cascades then trigger transcription factor proteins to bind enhancers and the identity of
these transcription factors, and their precise affinity for their target sequence combined with the syntax
of their binding, largely determines the precise transcriptional response of a given enhancer [22–24].
Although we still need to define the limits to the range at which enhancers can influence promoter
activity, it is clear that not all enhancers are able to interact with all promoters [25]. The range
and choice of promoters that enhancers influence is dependent on factors such as enhancer–promoter
specificity and whether they are separated by a third type of regulatory element called an insulator [26].
Insulator sequences, often referred to as TAD boundary elements, operate in combination with CTCF
and cohesin proteins and play a role in dividing the genome into topological associating domains or
TADs [27]. It has been suggested that TADs limit the influence of enhancers on other promoters [28],
although a full understanding of the blocking effects of insulators/TAD boundary domains remains to be
determined [29]. In addition to their identification through CTCF binding, TADs can be identified using
chromatin conformation capture techniques, such as 5C and HiC, which are able to detect long-distance
chromatin interactions [30]. Although we are still to fully understand the mechanisms modulating
these interactions, it is evident that loops of DNA formed by the threading of chromatin through
cohesin protein rings [27], interact within discrete but transient regions of the nucleus called chromatin
hubs (previously referred to as transcription factories) [31]. It has also been posited that much of
the long non-coding RNA (lncRNA) found in cells may derive from the active hauling of chromatin by
tethered RNApolII into these hubs [32]. This hypothesis is further supported by the observation that
regions of DNA on either side of active enhancers are transcribed by RNApolII [33]. Nevertheless,
before we can understand how enhancers work in maintaining health, and how polymorphisms
and epigenetic factors influence their activity, we must be able to reliably identify and functionally
characterize them.
3. Chromatin Markers
As previously highlighted, most of the major insights into identifying enhancer elements and an
appreciation of the importance of their biology have come from developmental biology. It could
be argued that other fields, which study the biology of complex human disease, lag behind in
terms of their identification and characterization of cell-type-specific enhancer regions that GWAS
suggest are important in the development of these diseases. Are there lessons that these fields can
learn from developmental biology? Thanks to efforts by developmental biologists, several histone
modifications and the interaction of certain co-factors have become widely accepted markers of active
enhancers. These include histone 3, which has a mono-methylated fourth lysine residue (H3K4me1)
and histone 3 acetylated on lysine 27 (H3K27Ac) [34]. These histone marks are detected using
chromatin-immunoprecipitation (ChIP) technologies that use antibodies raised against each modified
histone (Figure 1) [34]. The p300 co-factor, also detected using ChIP, another accepted marker of
enhancer activity and acts as a histone acetyl transferase (HAT), whose activity is responsible for
generating H3K27ac [35]. Furthermore, regions of chromatin that are transcriptionally active are often
found in an “open” configuration, where the DNA and histones making up the chromatin associate
more loosely. This “open” DNA can be detected using techniques such as DNAse-seq, which depends
on a DNAse enzyme gaining access to the DNA (Figure 1) [36], or the more recently developed
and amenable ATAC-seq that uses the Tn5 transposase to ligate “barcode” primers to open chromatin
to aid subsequent next generation sequencing(Figure 1) [37]. Yet another technique that has been
used to detect active enhancers is a technique called Cap Analysis of Gene Expression (CAGE) that
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detects enhancer activity by virtue of their bidirectional transcription [33]. The development of these
methods of identifying active markers has hugely accelerated our ability to functionally annotate
the non-coding genome. However, the extreme context-dependency demonstrated by many enhancers
ensures that finding the appropriate cellular context in which these enhancers are active, and thus
open to detection by the methods described above, is often problematic. This problem was effectively
illustrated through the study of enhancers that drive the expression of the SOX9 gene in the lower jaw,
where enhancer activity (H3K27ac, H3K4me1 and p300) could not be detected in stem cells but only
within primary embryonic cranial neural crest cells [19], demonstrating the strong context-dependency
of these enhancers.
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The issue of context-dependency is one that somewhat decreases the impact of the ENCODE
data in identifying context-dependent or cell-type-specific enhancers. Released with much fanfare
in 2012, the data generated by ENCODE depended mainly on a combination of high-throughput
next-generation sequencing and homogeneous cell culture in a large number of different human
cell lines [15]. Despite its undoubted success in terms of numbers of publications in high-profile
journals, the ENCODE data release was greeted by a fair degree of skepticism [38]. One of the most
contentious issues was the suggestion by ENCODE that regulatory regions were not well conserved [15].
The inference was that enhancer regions evolved rapidly in each species, a hypothesis that was later
supported by a study based on the comparison of enhancer markers (H3K27ac) and conservation
focusing on primary hepatocytes [39]. A further p300/CBP co-factor analysis in adult and foetal human
heart tissues also concluded that vertebrate enhancers evolved rapidly and were not well conserved
between species [40,41]. The conclusions of these studies were controversial as they appeared to fly
in the face of evolutionary theory [38]. Although histone methylation/acetylation, p300 and open
chromatin (DNase1 sensitivity and ATAC) are now widely accepted as proxies for active enhancer
regions, questions need to be asked regarding the relevance and suitability of the cell types used in
many of these studies. Thus, whilst it is likely that H3K27ac, H3K4me1 and p300 enhancer marks will
remain the gold standard in detecting enhancers, their relevance in identifying and characterizing
enhancers will only be as good as the cell lines used. One possible direction we can use to partly
address this concern is to identify enhancer by virtue of their conservation. For example, high levels of
sequence conservation are associated with both the Shh enhancer [18] and Pierre Robin sequence PRS
enhancer [19]. Another exemplary study of GWAS-associated SNPs associated with neuroblastoma
succeeded in identifying an SNP (rs2168101 G > T) within a highly conserved enhancer inside intron 1
of the LMO1 gene [42]. Taken together, it is clear that the majority of studies that have successfully
identified functional enhancer regions in higher vertebrates have also identified extensive conservation
in these regions.
4. An Evolutionary Perspective
The logic behind comparative genomics is based on the hypothesis that genomic sequences
critical to species survival change at a much slower rate through evolutionary time [43,44]. Prior to
the discovery and widespread use of active enhancer proxies such as p300, H3K4me1 and H3K27ac,
a number of studies had successfully identified cell-type-specific activity in the majority of conserved
regions identified using transgenic embryos [44]. The identification of these sequences in human DNA
involves the computer alignment of hundreds of vertebrate genome sequences available online through
portals such as ENCODE, EMSEMBL and the UCSC browser [43,44]. We also found that proven
cell-type-specific enhancers controlling the Msx1 gene, identified through painstaking functional
dissection and analysis in transgenic embryos [45], were highly conserved once comparison of genome
sequences of mice, humans and chickens became possible [46,47]. Moreover, intuitively, it makes little
sense that the complex syntax of transcription factor binding sites, that are essential for the function of
enhancers that support these complex cell-type-specific patterns displayed by many genes, should not
also be conserved to some degree [48]. This was further supported by the observation that nearly 10%
of the human genome is under selection and has been conserved during evolution despite only 1.7% of
the genome encoding proteins [49]. Whilst there is evidence of increased plasticity in the evolution of
the non-coding genome compared to the coding genome that can account for much of the observable
difference between different species and between individuals within a species [50], we will present
further evidence that there is a clear case for including comparative genomics in looking for functional
disease-associated enhancer sequences in the human genome (Figure 1).
5. Conserved Enhancers in Adult Brain Activity
In addition to our embryonic development, many aspects of adult human health are also
highly dependent on tightly controlled cell-type-specific gene regulation. For example, human health
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and homeostasis are tightly regulated by a myriad of different neuropeptides that need to be expressed
in precise regions of the hypothalamus, amygdala and sensory neurons to modulate appropriate
levels of food intake, mood and pain perception [51,52]. Thus, identification of the enhancer regions
that control the cell-type-specific expression of these neuropeptides, and how they might be affected
by polymorphic variation, will be critical to our understanding of health and disease. For example,
substance-P (SP; encoded by TAC1 gene) is a neuropeptide expressed in c-fibre sensory neurons
and the medial amygdala where it is critical to pain perception and mood modulation [53,54]. We first
used comparative genomics in species as diverse as mammals and birds to identify a highly conserved
enhancer that lay 158kb from the TAC1 gene, which drove reporter gene expression in SP expressing
amygdala neurons [55]. Later transgenic analysis of an even remoter conserved enhancer (214kb from
TAC1 gene) demonstrated its ability to not only drive reporter expression in SP expressing C-fibre
sensory neurons but to also switch reporter gene expression to larger diameter A-fibres in response to
inflammatory stimuli—an expression of SP associated with hyperalgesia [56–58].
We also used comparative genomics to explore the regulation of another neuropeptide; galanin
(encoded by the GAL gene) that played a role in mood modulation as well as preference for fat
and ethanol [51,59]. We identified a region of highly conserved DNA (GAL5.1) lying 42kb from
the GAL gene that we cloned into a reporter plasmid. Following microinjection of this plasmid into
the pronucleus of a mouse embryo and subsequent oviduct transfer (Figure 1) we found that GAL5.1
drove expression of the reporter gene in Gal expressing cells of the hypothalamus and amygdala of
resulting transgenic mice [60]. We also used CRISPR/CAS9 genome editing technologies (Figure 1) to
delete GAL5.1 from the mouse genome. This was achieved by injecting CAS9 mRNA and guideRNA
(gRNA), designed to direct the deletion of the GAL5.1 enhancer, into the cytoplasm of one-cell mouse
embryos. Following oviduct transfer and birth of these mice, we found a high proportion lacked
the GAL5.1 enhancer (Figure 1). Quantitative reverse transcriptase analysis of these lines showed a
major reduction in Gal expression in the amygdala and hypothalamus. In addition, these animals
demonstrated significantly reduced fat and alcohol consumption and reduced anxiety-like behavior
in males [61]. Quantitative analysis of two different allelic variants of the human GAL5.1 enhancer
identified significant differences in the activity of these variants in primary hypothalamic cells [60].
Most surprisingly, a parallel study of a large human cohort (UK Biobank) succeeded in identifying
an association between increased anxiety and ethanol consumption in males carrying the stronger
GAL5.1 allele [61]. Intriguingly, we were unable to identify chromatin markers such as H3K4me1,
H3K27ac or DNAse1 sensitivity within any of the enhancer that we have studied over the years using
available online databases such as the ENCODE consortium. The likely reason behind this observation
is that, because of the extreme tissue specificity of the enhancers we analyzed, they are inactive within
the cell types available to ENCODE and would, therefore, lack the histone markers, p300 and DNase
sensitivity marks diagnostic of active enhancers.
The next logical step in the in vivo analysis of enhancer function will be to reproduce the different
human disease-associated allelic variants of each enhancer in mice and analyze their effects on
the physiology and behavior of the resultant animals. This would likely require the humanization of
entire enhancer regions with either allelic variant and a comparison of the behavior of the different lines.
CRISPR-driven humanization of large regions of the mouse genome represents a challenging process
that, in addition to CAS9 and gRNA, requires the co-injection of repair template DNA, designed to
trigger the cells’ homology-directed repair pathway, into the nucleus of a 1-cell mouse zygote. Whilst this
approach has been successfully used to humanize gene coding regions in mice [62–64], it has yet to be
used to humanize enhancer regions. The alternative, and more conventional, strategy to humanization
involves embryonic stem (ES)-cell targeting and blastocyst microinjection [65]. However, ES-cell targeting
is an order of magnitude more expensive and time-consuming than CRISPR-based options thus placing
it outside the financial constraints of most small labs.
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6. Gene Regulation and Pharmacogenomics?
Despite major efforts to identify novel drug targets within the coding regions of the genome,
little or no attention has been paid to the possible role of the non-coding genome in altering drug
response or even as a drug target in its own right. In the past, a number of GWAS studies have identified
that, in addition to disease, the non-coding genome also acts as a reservoir of drug stratification loci that
alter the response to drugs between individuals within the population [66]. In an attempt to identify
drug stratification loci within the genome, we used comparative genomics to explore the regulation of
the gene (CNR1) encoding the cannabinoid-1 receptor (CB1). The pharmacogenomics of CB1 has gained
considerable interest following the legalization of therapeutic cannabinoids in many countries around
the world, including the legalization of recreational cannabis use in a number of states in the US [67].
We used comparative genomics to identify a polymorphic enhancer region within intron1 of the CNR1
locus that lay in strong linkage disequilibrium (LD; a phenomenon where groups of alleles travel
together in a population) with a group of SNPs that had been previously associated with addictive
behaviors [68]. Initial in-vitro analysis of this enhancer region showed considerable differences in
the enhancer activity of allelic variants [68]. As for GAL5.1, we used CRISPR genome editing to delete
this enhancer from the mouse genome but only achieved a relatively modest, although significant,
decrease in the hippocampal expression of the Cnr1 gene in these animals, suggesting regulatory
redundancy [69]. Nevertheless, behavioral analysis of these animals demonstrated a significant
difference in their response to CB1 agonism and alcohol intake [69], suggesting that despite its modest
effects on CNR1 expression, the Cnr1-intron 1 enhancer plays a role in CB1 function that has been
conserved for hundreds of millions of years. Taken together, these experiments suggest a future
direction for the analysis of the non-coding genome in the burgeoning field of pharmacogenetics.
7. Enhancers as Future Personalised Drug Targets?
Although a great deal is known of the interaction of enhancers and transcription factors, almost
nothing is known of the signal transduction pathways that influence these interactions [21]. In order
to identify the signal transduction pathways that influence the activity of the GAL5.1 enhancer,
we used a series of agonists and antagonist to identify the involvement of protein kinase C (PKC)
pathways in stimulating GAL5.1 activity whilst ruling out the involvement of protein kinase A (PKA)
or the MAPkinase pathways [60,61]. Critically, we were able to demonstrate that the allelic variant
of GAL5.1, associated with increase ethanol intake and anxiety, responded more strongly to PKC
activation than did the protective minor allele [60,61]. In another study, we observed that the C-allele
of a repressor region (rs12273363), associated with mood disorders, modulated the activity of BDNF
promoter 4 in an allele-specific manner following cell depolarization or the combined activity of PKA
and PKC pathways [70]. These studies lay the groundwork for developing a better understanding
of the “druggable” signal transduction pathways in the cell that control enhancer action, which may
eventually give us clues for the development of future personalised therapeutics.
8. Nature Versus Nurture: Epigenetics and the Functional Non-Coding Genome
CpG methylation is an epigenetic marker that is strongly affected by environmental factors
such as diet, early life stress, or the life-styles led by our parents [71]. Environmentally altered CpG
methylation, in turn, can modulate susceptibility to diseases such as depression, addiction and anxiety
in subsequent generations [72,73]. Although the effects of epigenetic modification of promoter regions
through CpG methylation is well established [73,74] there is also evidence that methylation of enhancer
regions affects their activity [75,76]. For example, decreased methylation of an enhancer responsible
for expression of the AgRP gene in the amygdala and hypothalamus was found to result from early
life stress (maternal separation). The results of this reduction in AgRP enhancer methylation was
an increase in AgRP gene expression and an increase in anxiety and depression-like behavior in
mice subjected to maternal separation [77]. Most intriguingly, allelic variation can often introduce
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or delete CpG dinucleotides within functional regulatory regions, rendering these enhancers more
or less susceptible to the effects of CpG methylation. For example, the GAL5.1 enhancer contains
two loci that modulate its cell-type-specific activity such that the GG haplotype has one more CpG
than the rarer CA haplotype [60,61]. Moreover, the enhancer within CNR1 intron 2 contains an SNP
whose disease-associated T-allele removes a CpG [78,79]. From these preliminary observations, we can
already see that polymorphic enhancer and promoter regions may serve as regions of the genome
where genetics and environment interact to ensure health or to exacerbate disease susceptibility.
9. Conclusions
A direction for the future understanding of the role of the non-coding genome in complex
disease has been presented. Thanks to its decreasing costs and increasing efficiency, the use of
next-generation sequencing (NGS) to produce whole-genome sequencing (WGS) technologies to
sequence the genomes of large human disease cohorts is poised to supersede GWAS as the method of
choice for identifying allelic variants associated with complex disease [80,81]. Another very promising
direction in determining the functional consequences of non-coding allelic variation is the analysis of
expression quantitative trait locus (eQTL) data as typified by the GTEx consortium [82]. This approach
is based on the statistical relationship between allelic variants and levels of gene expression on a
multi-tissue–whole-genome level. Recent successful use of eQTL analysis was able to detect regulatory
variants that conferred risk to ADHD, schizophrenia and bipolar disorder in prenatal brain tissues [83].
There are concerns, however, that the cascade of data coming from GWAS and eQTL analysis will
become a roaring deluge once WGS replaces GWAS as a routine way to analyze human disease cohorts.
Although there will inevitably be regions of the genome associated with human disease that are
unique to humans, it is likely that the majority of disease-causing variants will be in conserved functional
regions of the non-coding genome that control physiologies and behaviors common to all mammals [50].
Another advantage to initially studying conserved regions is the ability to model the phenotypic effects
of modifying enhancer regions common to both species (humans and mice), which cannot be done for
non-conserved sequences. Gaining an understanding of the genomic architecture of human disease
can only be built on the foundations of a robust functional annotation of the conserved non-coding
genome using in-vivo models. Most importantly, developing an understanding of enhancers in health,
and their role in disease, will require a root and branch re-education of the nascent scientific community
so that the next generation of scientists are ready for the challenges ahead.
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